Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Six Months ended September 30, 2019
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets active pharmaceutical ingredients (APIs), generics, biosimilars, and differentiated formulations globally.
Key Financial Metrics
Figures in millions of Indian Rupees (Rs.) unless otherwise noted. Convenience translation to U.S. dollars provided at Rs. 70.64 = $1.00.
| Metric | Six Months Ended Sep 30, 2019 | Three Months Ended Sep 30, 2019 |
|---|---|---|
| Revenues | Rs. 86,444 (U.S.$ 1,224) | Rs. 48,009 (U.S.$ 680) |
| Gross Profit | Rs. 47,479 (54.9% margin) | Rs. 27,620 (57.5% margin) |
| Profit Before Tax | Rs. 16,164 | Rs. 7,664 |
| Profit for the Period (Net Income) | Rs. 17,553 (U.S.$ 248) | Rs. 10,925 (U.S.$ 155) |
| Net Cash from Operating Activities | Rs. 19,939 | Filing text does not provide a clear value for the three-month period. |
| Cash and Cash Equivalents (Sep 30, 2019) | Rs. 3,012 (U.S.$ 43) | Rs. 3,012 (U.S.$ 43) |
| Total Borrowings (Short + Long Term) | Rs. 31,541 (U.S.$ 447) | Rs. 31,541 (U.S.$ 447) |
Material Changes vs. Prior Comparable Period
- Revenue Growth: Consolidated revenues increased 15% year-over-year (YoY) for the six months and 26% for the quarter ended September 30, 2019.
- Proprietary Products: Revenue surged 413% (six months) and 857% (quarter) primarily due to a one-time license fee of Rs. 7,229 million (U.S.$ 105.1 million) from the sale of U.S. rights for ZEMBRACE SYMTOUCH and TOSYMRATM to Upsher-Smith Laboratories.
- Global Generics: Revenue grew 8% (six months) and 7% (quarter), driven by new product launches and volume increases, partially offset by price erosion in North America.
- PSAI: Revenue grew 2% (six months) and 18% (quarter), driven by increased API sales.
- Profitability: Net profit increased 83% YoY for the six months and 117% for the quarter.
- Tax Benefit: A significant driver was a net tax benefit of Rs. 1,389 million (six months) and Rs. 3,261 million (quarter) resulting from the recognition of a deferred tax asset related to Minimum Alternate Tax (MAT) credits following a reduction in the Indian MAT rate.
- Impairment Charges: Selling, general, and administrative (SG&A) expenses increased due to an impairment charge of Rs. 3,551 million (U.S.$ 49.7 million) on intangible assets related to three products (tobramycin, ramelteon, and imiquimod) in the Global Generics segment.
- Other Income: Included a settlement payment of Rs. 3,457 million (U.S.$ 50 million) from Celgene regarding a Canadian patent dispute.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- License Sale: The sale of proprietary product rights to Upsher-Smith generated significant non-recurring revenue.
- Product Recall: The company voluntarily recalled ranitidine products in the U.S. due to NDMA contamination, recognizing Rs. 231 million in inventory write-downs and a Rs. 170 million refund liability.
- Impairment: Significant impairment of intangible assets due to adverse market conditions for recently launched generic products.
- Regulatory and Legal Risks:
- U.S. FDA: The company received a warning letter in 2015 regarding cGMP deviations. While several facilities have successfully closed audits, re-inspections are ongoing for the Srikakulam API facility. Other facilities have received "Voluntary Action Initiated" (VAI) or "No Action Initiated" (NAI) classifications.
- Patent Litigation: Ongoing litigation with Indivior regarding Suboxone sublingual film patents; the company successfully vacated a preliminary injunction and resumed sales.
- Antitrust: The company is a defendant in the U.S. Generic Pharmaceuticals Antitrust Pricing Litigation (MDL-2724), alleging price-fixing conspiracies. The company believes claims are without merit.
- Environmental: Ongoing proceedings in India regarding land and water pollution in the Patancheru and Bollaram areas. The Telangana State Pollution Control Board has sought retrospective recoveries, which the company intends to contest.
- Outlook: Management highlights a robust pipeline with 99 filings pending with the U.S. FDA (including 55 Paragraph IV filings). The company continues to focus on new product launches in North America, India, and Emerging Markets.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the permanence of the tax benefit derived from the MAT rate reduction and the likelihood of utilizing these credits in future periods.
- Impairment Impact: Assess the long-term impact of the Rs. 3,551 million impairment charge on the Global Generics segment's future profitability and product portfolio strategy.
- Regulatory Compliance: Monitor the status of the U.S. FDA re-inspection for the Srikakulam API facility and the outcome of the environmental litigation in India.
- Revenue Quality: Distinguish between recurring revenue growth and the one-time impact of the Upsher-Smith license fee (Rs. 7,229 million) when evaluating future growth rates.
- Antitrust Exposure: Review developments in the MDL-2724 antitrust litigation for potential financial liabilities.